The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer

Launched by LIN LIU · Nov 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the level of a medication called Sintilimab in the blood relates to its effectiveness and any side effects in patients with advanced gastric cancer. The researchers want to understand how this treatment works specifically in patients from China and find ways to predict who might benefit from it or experience adverse reactions. This information could help doctors tailor treatments for each patient, improving their chances of success and minimizing negative effects.

To participate in this trial, patients should have been diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and plan to receive Sintilimab. They should have a good performance status, meaning they are relatively healthy and expected to live for at least three more months. Participants will need to agree to follow the study procedures and provide informed consent. This trial is currently recruiting participants, and it aims to gather valuable data that could enhance the treatment of gastric cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A. Patients who were diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; B. Patients who plan to be treated with Sintilimab; C.ECOG score of 0-2; D. Expected survival ≥3 months; E. The patient who have good compliance, follow-up, and can cooperate with relevant treatment and examination; F. Agree to participate in the study and sign the informed consent
• Exclusion Criteria:
• • A. Patients who clinical information and data are incomplete; B. Patients who treated with immune checkpoint inhibitors within 6 months